The small-cap sector crawled beneath the struggling broad indices Monday despite surging names like XTL Biopharmaceuticals ( XTLB), which announced it began a phase IIb trial of Bicifadine for treatment of diabetic neuropathic (nervous-system-related) pain.

Shares of the Valley Cottage, N.Y., company were up 30.4% to $1.76.

InPlay Technologies ( NPLA), based in Phoenix, climbed on word of a purchase-order renewal for its thiNcoder rotary-switch technology. The customer, a "leading supplier of products for the global sleep and respiratory markets," agreed to buy at least one million units through Duraswitch licensees over the next 18 months for a new line of positive-airway-pressure-therapy products. InPlay shares were leaping 15.2% to $1.74.

Elsewhere, management-services firm Versar ( VSR) bounced 2.8% after swinging to a fiscal fourth-quarter profit of $803,000, as well as posting a more-than-tripled full-year profit of $5.3 million, or 62 cents a share. Full-year sales soared 68.7% to $102.7 million. Shares of the Springfield, Va., company were trading at $8.94.

On the downside today, however, was Cardica ( CRDC), which slid 15.4% to $8.39 after A.G. Edwards cut the stock to sell from buy. The analyst said its shares spiked too high after last week's announcement of two pioneering closed-chest bypass surgeries using a Cardica device that automates the attachment of a blood vessel graft to a coronary artery during bypass surgery.

If you liked this article you might like

Lackluster Finish for U.S. Stocks

Lackluster Finish for U.S. Stocks

Stocks Continue to Waver at the Flat Line

Stocks Continue to Waver at the Flat Line

Oil Slides as Stocks Post a Mixed Showing

Oil Slides as Stocks Post a Mixed Showing

Stocks Flutter Near the Flat Line

Stocks Flutter Near the Flat Line

Wall Street Falls Amid Inflation Talk

Wall Street Falls Amid Inflation Talk